Insiders Are Loading Up on This AI Biotech Stock!

Why are they so bullish? [Shield] AN OXFORD CLUB PUBLICATION [Wealthy Retirement]( [View in browser]( SPONSORED [WATCH NOW: Multimillionaire Trader Wows Thousands With "One Ticker Payouts" Demonstration]( [One Ticker Payout]( Research found that smart investors could have made top gains of... - 443% in 11 days - 89% in 11 days - 543% in nine days - 88% in seven days. All by trading just one ticker every week! Sound preposterous? [SEE THE PROOF HERE]( Editor's Note: Director of Trading Anthony Summers is on vacation this week, so in place of our Value Meter column, I'm passing along this message from Chief Investment Strategist Alexander Green. In 2018, a small group of insiders loaded up on nearly $4 million worth of stock in a little-known company called Tandem Diabetes Care (Nasdaq: TNDM). Those who followed their lead saw the chance to [turn $10,000 into over $189,000 in just one year](. That's a staggering 1,795% gain! Alex has been tracking insider moves like this for decades, and he's ready to share his [next big insider opportunity]( with you. [Click here to see details on Alex's top insider stock pick right now](... completely free of charge. - James Ogletree, Managing Editor [MARKET TRENDS]( [Beat the Market by Following Biotech Insiders]( [Alexander Green, Chief Investment Strategist, The Oxford Club]( [Alexander Green]( Over the past decade, investing in biotech stocks with insider buying has tripled the S&P 500's return. Tandem Diabetes Care (Nasdaq: TNDM) and Exscientia PLC (Nasdaq: EXAI) are prime examples of some I've recommended. The former was a particularly big winner, allowing my readers to lock in up to a 1,795% gain in less than one year. Needless to say, I'm bullish on the industry. But there's one big problem faced by most biotechs: Drug discovery. More specifically, how long drug discovery takes and how much it costs. Drug discovery hasn't changed much in the last century. It still takes up to a decade or even more in some cases to develop a new drug. It's a long, manual process with lots of trial and error (not to mention government red tape) that can be performed only by highly trained resources. Because of that, it's also astronomically expensive. The average cost to develop a new drug is $2.6 billion... That's a lot of money to shell out for a drug that may not even make the cut - a full 9 out of 10 drugs entering Phase 1 clinical trials never make it to market. They get shot down by the Food and Drug Administration (FDA), often for good reason. But by that point, it's already cost billions of dollars to develop them. That's changing, though. And it's changing fast. Artificial intelligence (AI) can make drug development a faster and cheaper process with fewer costly failures. It can shorten drug development times from a decade-plus on average to just a few short years and give us better, longer, healthier lives in the process. I recently found a company that is using AI to support the entire biotech industry. Because, unlike many biotech companies that focus on only one specific segment of the drug development process, this company helps other biotechs make new breakout discoveries. In fact, it has supported 80% of all FDA-approved novel drugs that have hit the market over the past five years. If you're taking a new drug, there's a good chance this company helped develop it. I'm expecting big things for this company because its insiders are piling in at a breakneck pace... I think the biggest growth is just on the horizon. That's based on the fact that insiders have loaded up on $1.45 million worth of shares in the last 12 months - with some of the fastest buying happening as we were coming into the end of 2023. Among the biggest purchases were those from the CEO, who bought 5,620 shares for just over $1 million, and the COO, who bought 1,322 shares for just under $250,000 - both in November 2023. That's a prime example of the cluster buying that I look for - and from two of the highest-ranking executives at the company to boot... And when I see high-level insiders plunk down big money on their own stocks, I know something big is likely to happen soon... SPONSORED [4,735% Revenue Surge: The Linchpin of Nvidia's AI Dominance?]( [Artificial Intelligence concept]( As Nvidia's new Blackwell chip sparks an AI revolution, one company is poised to skyrocket. This unsung hero's revenue could soar up to 4,735% in the next 12 months as tech titans line up to secure their groundbreaking technology. Early investors could see life-changing gains as this story unfolds. [Don't miss your chance to ride the AI mega-trend.]( Following the Insiders This company sits at a crossroads of AI, biotech and insider buying: two industries growing at an incredible pace plus the single greatest indicator I've ever seen in the market... [All in one stock.]( The company's incredible technology and the niche it's carved out in the biotech industry make it a great investment... But considering two of its highest-ranking executives are eating their own cooking to the tune of $1.2 million, [this goes from a great buy to an out-and-out incredible opportunity](. I'm bullish on the biotech industry, I'm bullish on AI and I've always been bullish on companies with massive insider purchases. This is not an opportunity you want to pass up, and [it's my No. 1 insider stock pick for this year](. [Find out more details here now.]( This strategy has delivered gains as high as 1,163% in just 90 days. And today, I'm seeing signs that we could be on the verge of another massive winner. [Click here to learn how you could potentially target 10X gains by Labor Day.]( Good investing, Alex [Leave a Comment]( [Investment U Conference 2025 - Ponte Vedra Inn & Club in Ponte Vedra Beach, Florida, March 30-April 2, 2025]( BUILD AND PROTECT YOUR WEALTH [Discover the Top Passive Income Opportunity for 2024...]( [How to Invest in the Dollar (When it Weakens)]( [Famous Trader Puts AI To The Test (You're Not Going To Believe This)]( [Why You're Not Making More Money]( MORE FROM WEALTHY RETIREMENT [Article]( [Prospect Capital’s 13.2% Yield Is Hard to Trust]( [Article]( [Is This Crypto Skeptic Starting to See the Light?]( [Article]( [Is Levi Strauss & Co. a Good Value After Its Sharp Decline?]( [Article]( [Marc’s Journey From Starving Actor to Renowned Investing Strategist]( [Facebook]( [Facebook]( [LinkedIn logo]( [LinkedIn]( [Email Share](mailto:?subject=A%20great%20piece%20from%20Wealthy%20Retirement...&body=From%20Wealthy%20Retirement:%0D%0A%0D%0AOver the past decade, investing in biotech stocks with insider buying has TRIPLED the S%26P 500%27s return...%0D%0A%0D [Email Share](mailto:?subject=A%20great%20piece%20from%20Wealthy%20Retirement...&body=From%20Wealthy%20Retirement:%0D%0A%0D%0AOver the past decade, investing in biotech stocks with insider buying has TRIPLED the S%26P 500%27s return...%0D%0A%0D [Push Alert]( [Push Alert]( SPONSORED [Yours Free! Top FIVE Dividend Stocks Right Now]( Marc Lichtenfeld - income expert and author of Get Rich with Dividends - is giving away his Ultimate Dividend Package... completely free of charge! You'll discover... - An "A"-rated, ultra-safe dividend stock with a huge 8% yield - Three of Marc's favorite "Extreme Dividend" stocks, which could supercharge your income - And finally, Marc's No. 1 dividend stock for a LIFETIME of income. [Click here to get the names and ticker symbols now](... before the download link expires. **NO CREDIT CARD REQUIRED!** [The Oxford Club]( You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. [Privacy Policy]( | [Whitelist Wealthy Retirement]( | [Unsubscribe]( © 2024 The Oxford Club, LLC All Rights Reserved The Oxford Club | [105 West Monument Street](#) | [Baltimore, MD 21201](#) North America: [877.808.9795](#) | International: [+1.443.353.4621](#) [Oxfordclub.com]( Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.